skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Other infiltrative disorders of skin and subcutaneous tissue
DOID EFO Endpoint Browser PheWeb
L12_OTHERINFILTRATIVESKIN
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
192 |
4. Check minimum number of eventsNone |
192 |
5. Include endpointsNone |
192 |
6. Filter based on genotype QC (FinnGen only) |
171 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L98
- Name in latin
- Aliae morbositates infiltrativae cutis et textus subcutanei
Similar endpoints
↥List of similar endpoints to
Other infiltrative disorders of skin and subcutaneous tissue
based on the number of shared cases.
Similar with more cases:
- Other disorders of skin and subcutaneous tissue, not elsewhere classified
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1124 | 634 | 485 |
| Only index persons | 1034 | 597 | 437 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 55.18 | 56.99 | 52.63 |
| Only index persons | 55.43 | 57.00 | 53.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 171 | 105 | 66 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | 57.08 | 56.51 | 57.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 176
- Matched controls
- 1760
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L98.6
ICD-10 Finland
Other infiltrative disorders of skin and subcutaneous tissue
+∞
88.1
77
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
20.3
80.8
75
62
L98.69
ICD-10 Finland
Other infiltrative disease of the skin and subcutaneous tissue
+∞
54.0
49
*
L98.60
ICD-10 Finland
Pseudolymphoma of the skin
+∞
30.1
28
*
L98.64
ICD-10 Finland
Benign lymphocyte infiltration into the skin [Jessner-Kanof]
+∞
21.3
20
*
L98.63
ICD-10 Finland
Lymphocytoma of the skin
+∞
18.0
17
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.0
16.2
63
216
D07AC01
ATC
betamethasone; topical
3.3
13.7
93
447
L93.0
ICD-10 Finland
Discoid lupus erythematosus
151.2
13.6
14
*
D07AD01
ATC
clobetasol; topical
3.8
13.5
52
175
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
5.9
13.4
26
50
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
19.2
12.8
19
11
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.9
12.0
29
68
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.6
9.6
19
37
D07AC13
ATC
mometasone; topical
2.8
9.4
68
324
P01BA02
ATC
hydroxychloroquine; oral
4.0
9.1
28
79
L98.9
ICD-10 Finland
Disorder of skin and subcutaneous tissue, unspecified
21.3
8.6
12
6
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
4.2
8.4
24
64
D07AB08
ATC
desonide; topical
3.4
8.0
32
108
L82
ICD-10 Finland
Seborrhoeic keratosis
2.9
7.9
43
175
L93.2
ICD-10 Finland
Other local lupus erythematosus
+∞
7.3
7
*
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
31.4
7.2
9
*
E0000UV, ,
ATC
2.3
7.0
86
513
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
72.4
6.5
7
*
S18
ICPC
Laceration/cut
2.2
6.1
94
604
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
173
3.34
10.39
6.3
5.6
214.55
238.56
u/l
1.62
42
165
122
880
2.26
5.82
12.5
10.8
3.69
4.00
e9/l
1.06
107
767
20
63
3.45
5.51
2.1
1.8
2.26
8.01
iu/ml
—
5
12
48
249
2.28
5.16
2.5
1.9
—
—
—
0
0
25
102
2.69
4.45
1.4
1.4
—
—
—
0
0
7
6
12.07
4.31
1.6
2.2
—
—
—
0
0
36
180
2.26
4.17
2.5
1.8
—
—
—
0
0
14
44
3.37
3.87
1.1
1.3
—
—
—
0
0
21
85
2.67
3.80
1.9
1.7
—
—
—
0
0
36
188
2.15
3.74
2.2
1.8
—
—
—
0
0
103
776
1.79
3.48
9.8
6.9
1.21
1.21
mmol/l
0.13
93
676
41
232
2.00
3.43
2.7
2.0
29.56
29.14
s
0.22
41
227
50
306
1.89
3.33
5.2
3.8
255.71
228.06
ng/l
0.06
38
235
13
44
3.11
3.21
1.7
1.4
—
—
—
0
0
95
712
1.73
3.15
3.5
2.9
139.29
111.60
ug/l
0.62
87
664
137
1147
1.88
3.03
6.3
4.4
10.74
12.00
mm/h
0.76
130
1061
7
14
5.16
2.75
1.4
1.5
—
—
—
0
0
12
41
3.07
2.68
1.7
1.7
—
—
—
0
0
12
41
3.07
2.68
1.5
1.6
—
—
—
0
0
37
223
1.83
2.54
10.5
6.5
103.49
104.22
mmol/l
0.41
37
223
8
21
3.94
2.49
1.6
1.5
—
—
—
0
0
14
58
2.54
2.44
2.9
2.3
—
—
—
0
0
58
407
1.63
2.32
3.3
3.0
340.26
347.07
umol/l
0.17
53
348
6
13
4.74
2.29
1.8
2.3
—
—
—
0
0
6
13
4.74
2.29
1.8
2.3
—
—
—
0
0
6
13
4.74
2.29
1.8
2.3
—
—
—
0
0
9
31
3.00
2.10
1.8
1.6
—
—
—
0
0
5
10
5.11
2.08
6.4
1.9
14.00
13.70
%
—
5
10
6
15
4.10
2.05
1.7
1.1
347.33
865.55
u/l
—
6
15
10
38
2.73
2.04
1.4
1.5
—
—
—
0
0
12
51
2.45
2.00
3.2
2.6
0.00
0.09
g/l
0.49
12
51
12
51
2.45
2.00
1.1
1.1
—
—
—
0
0
50
350
1.60
1.99
2.4
1.8
1.33
1.35
mg/l
0.01
43
277
62
460
1.54
1.91
1.9
1.7
23.33
21.64
nmol/l
0.45
51
386
9
34
2.73
1.89
1.8
1.3
—
—
—
0
0
60
444
1.53
1.86
4.3
3.0
0.15
0.37
e6/l
1.86
46
320
5
12
4.25
1.83
1.2
1.1
—
—
—
0
0
9
35
2.65
1.83
1.8
1.6
—
—
—
0
0
87
699
1.48
1.81
2.7
2.4
80.19
76.53
nmol/l
0.60
78
623
16
81
2.07
1.81
1.1
1.0
—
—
—
0
0
42
289
1.60
1.78
1.3
1.3
37.32
43.92
iu/ml
0.12
17
91
40
274
1.60
1.73
2.6
2.8
0.35
1.02
e6/l
2.15
22
144
6
19
3.23
1.67
1.2
1.2
—
—
—
0
0
16
84
2.00
1.66
2.9
2.8
24.11
24.49
mmol/l
0.17
16
84
142
1276
1.58
1.61
25.8
19.6
13.65
13.68
%
0.11
142
1268
11
50
2.28
1.60
1.1
1.2
—
—
—
0
0
11
50
2.28
1.60
3.0
2.7
0.00
0.00
g/l
-0.00
11
50
87
715
1.43
1.54
8.1
6.2
1.20
1.21
mmol/l
0.58
80
663
5
15
3.40
1.53
1.0
1.4
—
—
—
0
0
6
21
2.92
1.52
1.7
1.3
—
—
—
0
0
6
21
2.92
1.52
1.7
1.5
49.37
53.61
ug/l
—
6
21
21
125
1.77
1.52
4.7
3.0
61.38
63.16
ml/min/173m2
—
8
55
49
363
1.48
1.48
1.3
1.3
0.98
1.24
u/ml
0.18
16
101
98
829
1.41
1.44
4.4
3.8
0.00
0.00
estimate
-0.00
18
175
16
89
1.88
1.42
2.8
2.4
0.58
0.63
%
0.35
16
89
6
23
2.66
1.38
1.3
1.1
—
—
—
0
0
77
630
1.40
1.35
4.3
3.7
0.20
0.00
estimate
0.48
15
142
83
689
1.39
1.33
2.8
2.0
92.73
98.50
pmol/l
0.70
42
330
106
917
1.39
1.32
3.2
3.1
—
—
—
0
0
98
837
1.39
1.32
4.5
3.9
0.10
9.23
estimate
0.49
20
176
6
25
2.45
1.25
1.3
1.2
—
—
—
0
0
6
25
2.45
1.25
2.2
1.6
—
—
—
0
0
5
19
2.68
1.22
1.2
1.3
—
—
—
0
0
6
26
2.35
1.19
1.7
1.7
—
—
—
0
0
6
26
2.35
1.19
1.8
1.9
—
—
—
0
0
37
274
1.44
1.12
1.2
1.3
20.42
10.71
u/ml
0.32
18
96
130
1182
1.38
1.08
5.4
4.4
14.65
14.81
pmol/l
0.31
125
1075
97
845
1.33
1.07
4.5
3.9
0.21
0.02
estimate
0.41
19
171
7
34
2.10
1.04
1.6
1.3
—
—
—
0
0
10
53
1.94
1.03
2.9
2.1
—
—
—
0
0
7
35
2.04
1.01
3.4
1.2
—
—
—
0
0
48
383
1.35
0.94
2.4
2.2
2.34
2.94
mg/l
1.26
42
330
13
78
1.72
0.94
1.0
1.3
—
—
—
0
0
6
27
2.26
0.94
1.3
1.2
3.77
3.60
mmol/l
—
6
22
15
94
1.65
0.94
18.9
8.2
26.15
24.81
mmol/l
1.12
15
94
9
52
1.77
0.94
3.0
1.8
—
—
—
0
0
34
257
1.40
0.92
2.8
3.0
0.62
3.20
e6/l
2.93
15
128
35
266
1.39
0.92
1.5
1.5
—
—
—
0
0
6
30
2.03
0.88
2.0
1.7
—
—
—
0
0
6
32
1.91
0.82
1.3
1.1
—
—
—
0
0
6
32
1.91
0.82
2.5
1.5
—
—
—
0
0
8
47
1.73
0.82
2.0
1.7
31.13
38.36
nmol/l
—
8
47
8
48
1.70
0.80
4.0
5.7
23.29
160.10
mg/l
—
8
43
8
48
1.70
0.80
4.0
5.7
43.87
26.61
mg/l
—
8
43
56
468
1.29
0.79
4.3
3.3
0.20
0.00
estimate
0.48
15
137
60
507
1.28
0.78
2.9
2.5
63.37
75.79
u/l
0.42
54
472
17
116
1.52
0.77
2.6
2.3
4.17
6.65
ug/l
1.07
12
103
101
912
1.25
0.74
7.8
4.9
6.31
6.62
mmol/l
1.33
101
861
5
26
1.95
0.71
2.0
1.6
—
—
—
0
0
15
102
1.51
0.70
1.9
1.9
2.91
3.56
mmol/l
—
10
79
156
1493
1.39
0.67
23.6
15.4
22.23
21.84
mg/l
0.06
133
1226
30
239
1.31
0.60
1.6
1.4
—
—
—
0
0
33
401
0.78
0.59
3.6
2.2
—
—
—
0
0
6
40
1.52
0.52
1.2
1.4
—
—
—
0
0
20
154
1.34
0.51
3.5
3.2
—
—
—
0
0
7
46
1.54
0.49
1.0
1.2
—
—
—
0
0
7
46
1.54
0.49
1.0
1.2
—
—
—
0
0
168
1640
1.54
0.47
32.3
23.6
4.47
4.48
e12/l
0.17
162
1608
80
729
1.18
0.47
4.9
2.8
—
—
estimate
—
0
0
42
361
1.21
0.46
4.3
3.9
1.02
1.02
kg/l
0.95
28
227
0
15
0.00
0.41
0.0
4.1
—
27.13
—
0
8
5
35
1.44
0.39
2.4
2.2
—
—
—
0
0
146
1409
1.21
0.39
6.5
5.4
2.09
1.91
mu/l
0.85
139
1295
151
1463
1.23
0.37
23.1
15.1
79.55
80.22
ml/min/173m2
0.15
142
1362
16
130
1.25
0.30
1.6
1.4
—
—
—
0
0
54
494
1.13
0.29
3.5
3.3
2178.32
1090.60
ng/l
0.87
48
424
143
1469
0.86
0.28
5.7
5.2
5.80
5.96
mmol/l
1.19
136
1354
21
178
1.20
0.28
4.1
4.8
3.05
12.56
ug/l
2.45
15
146
11
86
1.30
0.27
3.5
3.1
4.39
4.42
pmol/l
0.05
11
75
9
75
1.21
0.25
2.1
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
6
49
1.23
0.20
1.2
1.4
43.88
28.63
iu/l
—
6
44
57
534
1.10
0.20
5.4
3.8
13.32
11.46
mg/mmol
0.08
41
313
62
592
1.07
0.14
4.1
4.0
25.65
35.63
ng/l
0.66
43
441
5
45
1.11
0.10
1.2
1.2
1.40
1.56
g/l
—
5
45
142
1439
0.93
0.10
4.8
4.3
1.26
1.27
mmol/l
0.03
132
1316
5
48
1.04
0.09
1.2
1.2
1.12
0.91
g/l
—
5
48
37
352
1.06
0.08
4.3
4.4
23.85
22.20
%
0.22
13
160
15
164
0.91
0.08
8.9
7.1
—
—
—
0
0
12
131
0.91
0.06
2.3
2.1
—
—
—
0
0
150
1512
0.95
0.05
5.3
5.0
1.44
1.48
mmol/l
0.66
144
1396
26
270
0.96
0.03
3.3
3.1
0.57
0.74
ug/l
0.83
18
160
153
1539
0.96
0.03
6.3
5.9
2.62
2.71
mmol/l
0.58
146
1423
26
251
1.04
0.03
1.5
1.7
1096.42
1178.95
nmol/l
0.19
19
189
10
94
1.07
0.01
2.0
2.2
—
—
—
0
0
46
461
1.00
0.00
5.4
3.8
0.00
0.00
estimate
-0.00
17
160
16
155
1.04
0.00
2.1
2.2
—
—
—
0
0
152
1518
1.01
0.00
5.5
5.1
4.56
4.64
mmol/l
0.39
147
1411
0
8
0.00
0.00
0.0
4.4
—
4.56
—
0
8
0
8
0.00
0.00
0.0
4.4
—
9.78
—
0
8
5
49
1.02
-0.00
1.4
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
62
0.97
-0.00
3.7
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
8
79
1.01
-0.00
2.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
90.54
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.3
—
222.50
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_OTHERINFILTRATIVESKIN and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERINFILTRATIVESKIN | 1.16 [0.89, 1.5] | 0.264 |
| Birth year | 0.994 [0.99, 1.0] | 0.159 |
During the follow-up period (1.1.1998 — 31.12.2019), 82 out of 583 females with L12_OTHERINFILTRATIVESKIN died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_OTHERINFILTRATIVESKIN | 1.305 [0.99, 1.71] | 0.055 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 442 males with L12_OTHERINFILTRATIVESKIN died.
Mortality risk
Mortality risk for people of age
years, who have L12_OTHERINFILTRATIVESKIN.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.082% | 0.224% |
| 5 | 0.767% | 1.307% |
| 10 | 1.624% | 3.239% |
| 15 | 3.128% | 6.275% |
| 20 | 5.646% | 10.793% |
Relationships between endpoints
↥Index endpoint: L12_OTHERINFILTRATIVESKIN – Other infiltrative disorders of skin and subcutaneous tissue
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data